Diabetologie und Stoffwechsel 2025; 20(S 01): S39-S40
DOI: 10.1055/s-0045-1807431
Abstracts | DDG 2025
Poster
Posterwalk 4: Klinische Diabetologie Typ-1 & Typ-2 Diabetes

Impact of Age on the Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Insulin in Type 2 Diabetes (ONWARDS 1–5)

Authors

  • K Milek

    1   Diabetologische Schwerpunktpraxis, Diabetologische Schwerpunktpraxis, Hohenmölsen – Weißenfels, Germany

  • AG D. Vianna

    2   Hospital Nossa Senhora das Graças, Curitiba Diabetes Center, Department of Endocrine Diseases, Curitiba, Brazil

  • C Desouza

    3   University of Nebraska Medical Center, University of Nebraska Medical Center, Omaha, Nebraska, United States

  • C Laugesen

    4   Novo Nordisk A/S, Medical & Science, Søborg, Denmark

  • M Fragão Marques

    5   Faculdade de Medicina da Universidade do Porto, Departamento de Cirurgia e Fisiologia, Porto, Portugal

  • P H Nielsen

    6   Novo Nordisk A/S, Biostatistics RD, Søborg, Denmark

  • S S Shaikh

    7   Prince Aly Khan Hospital, Department of Endocrinology, Mumbai, India

  • I Lingvay

    8   Department of Internal Medicine and Peter O’Donnell School of Public Health, Endocrinology Division, Dallas, United States
Weitere Informationen
Auch verfügbar auf
 

Introduction & Objective: This post hoc analysis assessed the treatment effects of once-weekly insulin icodec (icodec) vs once-daily (OD) basal insulin comparators across different age groups in adults with T2D.

Methods: Efficacy outcomes and hypoglycemia rates for icodec vs OD comparators across three age subgroups (<55, 55-64 and≥65 years) were assessed, by trial, in insulin-naïve (ONWARDS 1, 3, 5) and insulin-treated (ONWARDS 2, 4) adults with T2D.

Results: There were no statistically significant treatment by subgroup interactions for change in A1C from baseline to planned end of treatment (EOT). A larger reduction in A1C with icodec was seen across age subgroups in ONWARDS 1-5, except for individuals≥65 years in ONWARDS 4, where the opposite trend was seen. Overall, rates of clinically significant and severe hypoglycemic episodes were low in both treatment arms across age subgroups. In ONWARDS 1-5, the proportions of individuals achieving A1C<7% without clinically significant or severe hypoglycemic episodes at planned EOT were higher for icodec vs OD comparators irrespective of age, except for individuals<55 and≥65 years in ONWARDS 4; no statistically significant difference was seen in the treatment by subgroup interaction across different age subgroups.

Conclusion: Overall, efficacy and hypoglycemia outcomes were consistent for icodec vs OD comparators irrespective of age.



Publikationsverlauf

Artikel online veröffentlicht:
28. Mai 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany